Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 27;7(4):169-175.
doi: 10.5194/jbji-7-169-2022. eCollection 2022.

Locally delivered antistaphylococcal lysin exebacase or CF-296 is active in methicillin-resistant Staphylococcus aureus implant-associated osteomyelitis

Affiliations

Locally delivered antistaphylococcal lysin exebacase or CF-296 is active in methicillin-resistant Staphylococcus aureus implant-associated osteomyelitis

Melissa Karau et al. J Bone Jt Infect. .

Abstract

Introduction: Staphylococcus aureus is the most common cause of orthopedic infections and can be challenging to treat, especially in the presence of a foreign body. The antistaphylococcal lysins exebacase and CF-296 have rapid bactericidal activity, a low propensity for resistance development, and synergize with some antibiotics. Methods: Rabbit implant-associated osteomyelitis was induced by drilling into the medial tibia followed by locally delivering exebacase, CF-296, or lysin carrier. A titanium screw colonized with methicillin-resistant S. aureus (MRSA) IDRL-6169 was inserted. Intravenous daptomycin or saline was administered and continued daily for 4 d. On day 5, rabbits were euthanized, and the tibiae and implants were collected for culture. Results were reported as log 10 colony forming units (cfu) per gram of bone or log 10 cfu per implant, and comparisons among the six groups were performed using the Wilcoxon rank sum test. Results: Based on implant and bone cultures, all treatments resulted in significantly lower bacterial counts than those of controls ( P 0.0025 ). Exebacase alone or with daptomycin as well as CF-296 with daptomycin were more active than daptomycin alone ( P 0.0098 ) or CF-296 alone ( P 0.0154 ) based on implant cultures. CF-296 with daptomycin was more active than either CF-296 alone ( P = 0.0040 ) or daptomycin alone ( P = 0.0098 ) based on bone cultures. Conclusion: Local delivery of either exebacase or CF-296 offers a promising complement to conventional antibiotics in implant-associated infections.

PubMed Disclaimer

Conflict of interest statement

Robin Patel declares financial support (grants) from ContraFect Corporation, TenNor Therapeutics Limited, and BioFire Diagnostics. Robin Patel is a consultant to Curetis, Next Gen Diagnostics, PathoQuest, Selux Diagnostics, 1928 Diagnostics, PhAST, Torus Biosystems, Day Zero Diagnostics, Mammoth Biosciences, and Qvella Corporation; monies are paid to Mayo Clinic. Mayo Clinic and Robin Patel have a relationship with Pathogenomix. Robin Patel has research supported by Adaptive Phage Therapeutics. Mayo Clinic has a royalty-bearing know-how agreement and equity in Adaptive Phage Therapeutics. Robin Patel is also a consultant to Netflix and CARB-X. In addition, Robin Patel has a patent on PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an anti-biofilm substance issued. Robin Patel receives honoraria from the NBME, Up-to-Date, and the Infectious Diseases Board Review Course.

Figures

Figure 1
Figure 1
Scanning electron microscopy of the MRSA-seeded implant.
Figure 2
Figure 2
Surgical procedure: an incision was made over the left medial tibia, and the smooth flat portion was exposed (a); using a micro drill, a hole was created through the cortical bone into the medullary cavity (b, c); a total of 2 mL of water (d) followed by 0.6 mL of lysin or lysin carrier (e) was injected; and a seeded implant was inserted (f), tightened with a screwdriver (g), and confirmed to be secure (h).
Figure 3
Figure 3
Medial and supine X-rays of the left rabbit tibia to show implant placement (arrow).
Figure 4
Figure 4
Implant time–kill study. Titanium screws grown overnight with MRSA IDRL-6169 were placed in 0.1 mL of lysin carrier, exebacase (10.64 mg mL -1 ), or CF-296 (10.16 mg mL -1 ). After 1, 2, 4, 8, 12, or 24 h, three screws each were processed for quantitative culture and results were reported as log 10  cfu per implant.
Figure 5
Figure 5
Quantities of MRSA recovered from bones (a) and implants (b) on day 5. Dots represent values from individual animals; n=10 per group; horizontal lines represent median values. Asterisks indicate significant reductions compared to * saline/carrier ( P0.0025 ), ** daptomycin/carrier ( P0.0098 ), or *** saline/CF-296 ( P0.0154 ). (Note that slashes depict the treatment grouping, with the top being the systemic treatment given daily and the bottom being the local treatment administered at the time of surgery.)

Similar articles

Cited by

References

    1. Alder KD, Lee I, Munger AM, Kwon H-K, Morris MT, Cahill SV, Back J, Kristin EY, Lee FY. Intracellular Staphylococcus aureus in bone and joint infections: A mechanism of disease recurrence, inflammation, and bone and cartilage destruction. Bone. 2020;141:115568. doi: 10.1016/j.bone.2020.115568. - DOI - PubMed
    1. Asempa TE, Abdelraouf K, Carabeo T, Schuch R, Nicolau DP. Synergistic activity of exebacase (CF-301) in addition to daptomycin against Staphylococcus aureus in a neutropenic murine thigh infection model. Antimicrob Agents Chemother. 2019;64:e02176–02119. - PMC - PubMed
    1. Chambers HF, Basuino L, Diep B, Steenbergen J, Zhang S, Tattevin P, Alder J. Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis. Antimicrob Agents Chemother. 2009;53:1463–1467. - PMC - PubMed
    1. Direct lysis of resistant pathogen trial of exebacase (DISRUPT), NCT04160468 [Internet] Clinicaltrials.gov; [last access: 24 September 2021]. 2021. http://clinicaltrials.gov.
    1. Cobb LH, Park J, Swanson EA, Beard MC, McCabe EM, Rourke AS, Seo KS, Olivier AK, Priddy LB. CRISPR-Cas9 modified bacteriophage for treatment of Staphylococcus aureus induced osteomyelitis and soft tissue infection. PLoS One. 2019;14:e0220421. doi: 10.1371/journal.pone.0220421. - DOI - PMC - PubMed